Zelira Therapeutics (FRA:G1G) Shares Outstanding (Basic Average): 11.62 Mil (As of Jun. 2025)


FRA:G1G Zelira Therapeutics Ltd FRA:G1G
1 GF Score
Price €0.30
GF Value €0.07
! 7 Warning Signs
View Full Analysis

What is Zelira Therapeutics Shares Outstanding (Basic Average)?

Zelira Therapeutics FRA:G1G 1 Shares Outstanding (Basic Average) is 11.62 Mil as of Jun. 2025. GuruFocus rates FRA:G1G with a GF Score™ of 1/100 and a GF Value™ of €0.07. The stock has 7 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Zelira Therapeutics's average basic shares outstanding for the quarter that ended in Jun. 2025 was 11.62 Mil.


Zelira Therapeutics  (FRA:G1G) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Zelira Therapeutics Shares Outstanding (Basic Average) Related Terms


Zelira Therapeutics Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Shares Outstanding (Basic Average) Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.63 8.04 10.07 11.35 11.48

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.56 11.35 11.35 11.35 11.62
FRA:G1G
1GF Score
Zelira Therapeutics Ltd FRA:G1G
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelira Therapeutics Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 11.62 Mil mean?
Zelira Therapeutics (FRA:G1G) has a Shares Outstanding (Basic Average) of 11.62 Mil as of Jun. 2025. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Shares Outstanding (Basic Average) too high?
Zelira Therapeutics' current Shares Outstanding (Basic Average) is 11.62 Mil. Overall, Zelira Therapeutics has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does Zelira Therapeutics' Shares Outstanding (Basic Average) compare to ENSC and PPCB?
Zelira Therapeutics' Shares Outstanding (Basic Average) of 11.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Shares Outstanding (Basic Average) is 11.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (FRA:G1G) has a current Shares Outstanding (Basic Average) of 11.62 Mil. The stock's GF Value™ is €0.07, compared to a current price of €0.30 — trading 328.6% above its estimated fair value. The current Shares Outstanding (Basic Average) is 11.62 Mil. Zelira Therapeutics' overall GF Score™ is 1/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Zelira Therapeutics (FRA:G1G), the current Shares Outstanding (Basic Average) is 11.62 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zelira Therapeutics (FRA:G1G) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of €0.30 is trading 328.6% above its estimated GF Value™ of €0.07.

Key valuation signals for FRA:G1G:

  • Shares Outstanding (Basic Average): 11.62 Mil
  • GF Value™: €0.07 vs. price of €0.30 (328.6% above fair value)
  • GF Score™: 1/100 with 7 warning signs

No single metric tells the full story. See the FRA:G1G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
1GF Score

Get the complete analysis for FRA:G1G

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price
€0.07
GF Value